Penile Cancer Treatment Costs in England
BACKGROUND:
Penile
cancer is a rare malignancy in Western countries, with an incidence rate of
around 1 per 100,000. Due to its rarity, most treatment recommendations are
based on small trials and case series reports. Furthermore, data on the
resource implications are scarce. The objective of this study was to estimate
the annual economic burden of treating penile cancer in England between 2006
and 2011 and the cost of treating a single case based on a modified version of
the European Association of Urology penile cancer treatment guidelines.
METHODS:
A
retrospective (non-comparative) case series was performed using data extracted
from Hospital Episode Statistics. Patient admission data for invasive penile
cancer or carcinoma in situ of the penis was extracted by ICD-10 code and
matched to data from the 2010/11 National Tariff to calculate the mean number
of patients and associated annual cost. A mathematical model was simultaneously
developed to estimate mean treatment costs per patient based on interventions
and their associated outcomes, advised under a modified version of the European
Association of Urologists Treatment Guidelines.
RESULTS:
Approximately
640 patients per year received some form of inpatient care between 2006 and
2011, amounting to an average of 1,292 spells of care; with an average of 48
patients being treated in an outpatient setting. Mean annual costs per invasive
penile cancer inpatient and outpatient were £3,737 and £1,051 respectively,
with total mean annual costs amounting to £2,442,020 (excluding high cost
drugs). The mean cost per case, including follow-up, was estimated to be £7,421
to £8,063. Results were sensitive to the setting in which care was delivered.
CONCLUSIONS:
The
treatment of penile cancer consumes similar levels of resource to other
urological cancers. This should be factored in to decisions concerning new
treatment modalities as well as choices around resource allocation in
specialist treatment centres and the value of preventative measures.
Below: Invasive penile cancer cost distribution per care type. *Excludes chemotherapy and radiotherapy. Note: 2010 figures are based on preliminary data
- 1Sanofi Pasteur MSD, Mallards Reach, Bridge Avenue, Maidenhead, Berks, SL6 1QP, UK. skeeping@spmsd.com.
- 2Pharmerit Ltd, Enterprise House, Innovation Way, York, YO10 5NQ, UK. mtempest@pharmerit.com.
- 3Pharmerit Ltd, Enterprise House, Innovation Way, York, YO10 5NQ, UK. sstephens@pharmerit.com.
- 4Pharmerit Ltd, Enterprise House, Innovation Way, York, YO10 5NQ, UK. scarroll@spmsd.com.
- 5The Christie NHS Foundation Trust, University Hospital of South Manchester, Wilmslow Road, Manchester, M20 4BX, UK. vijay.sangar@nhs.net.
- BMC Public Health. 2015 Dec 29;15(1):1305. doi: 10.1186/s12889-015-2669-2.
No comments:
Post a Comment